Dr. Michael Dunne and Dr. Paul Miller of Pfizer got into antibiotic development because they wanted to make a difference in the lives of patients. But the obstacle course of scientific, economic, and regulatory barriers has lead to a reduction in investment in new antibiotics, just at a time of growing medical need...
Antibiotics: A Vital Resource
Bacterial infections that cannot be cured by existing antibiotics are becoming more common every day and are exacting a terrible price on patients and healthcare providers in the United States.
A supply of effective and affordable antibiotics cannot be sustained without changes to the real-world incentives facing patients, physicians, hospitals, insurers, and pharmaceutical manufacturers.
Our inaugural report, Extending the Cure: Policy Responses to the Growing Threat of Antibiotic Resistance, is a comprehensive study that explores incentive-based policies to protect antibiotic effectiveness, a valuable shared resource.
What's New
-
Research by ETC’s David L. Smith noted in The New Yorker.
-
New research on VRE from ETC’s Eili Klein.
-
ETC comments on recent MRSA research.